Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing a development strategy that bridges biomedical literature analysis with therapeutic development, as demonstrated at Drug Discovery 2026 in Burlingame, California. Scott Myers, Product Manager, and Saran Saund, Chief Business Officer, presented the company's PDAOAI platform and its application in hepatocellular carcinoma (HCC) research, signaling a potential shift in how researchers approach drug discovery.
Myers presented "The Infinity Problem: AI Search Aggregation for Biomedical Knowledge Discovery in Drug Development" on October 7, describing how PDAOAI searches and organizes an index of approximately 29 million PubMed abstracts to support focused biomedical research. The platform addresses the challenge of navigating vast scientific literature, enabling researchers to extract relevant insights efficiently. This capability could significantly reduce the time and resources required to identify promising drug targets and understand disease mechanisms.
On October 8, Saund followed with an HCC case study, presenting a four-gene HCC signature associated with survival in an exploratory discovery analysis and an independent Japanese cohort. This signature, linked to the mTOR pathway, exemplifies how disease-specific literature analysis can generate actionable hypotheses. The findings underscore the potential of PDAOAI to uncover novel biomarkers and therapeutic targets, which could lead to more personalized treatment approaches for liver cancer.
The presentations highlight the importance of integrating AI-driven literature analysis into drug development. By leveraging PDAOAI, Oncotelic aims to enhance hypothesis generation and streamline research workflows, ultimately accelerating the translation of scientific evidence into clinical applications. Furthermore, BIO REBOOT, an initiative that connects the platform's research capabilities with potential funding and development support for selected projects, could provide a pathway for advancing promising discoveries.
These developments matter because they demonstrate a practical application of AI in biomedical research, moving beyond theoretical benefits to tangible outputs like the HCC signature. For investors and the pharmaceutical industry, Oncotelic's approach could represent a cost-effective method to identify and validate drug candidates, potentially improving success rates in clinical trials. The company's efforts align with broader trends in leveraging big data and AI to transform drug discovery, a field where innovation is critical to addressing unmet medical needs.
For ongoing updates, the latest news and updates relating to OTLC are available in the company's newsroom at ibn.fm/OTLC. Oncotelic's participation at Drug Discovery 2026 reflects its commitment to pioneering solutions that bridge computational analysis and therapeutic development.
